Gene therapy using FGFR-inhibiting vector against lung squamous cell carcinoma

点击翻译按钮获取中文摘要

We performed an experimental study on the gene therapy using a FGFR-inhibiting vector for a new treatment against lung squamous cell carcinomas. First, we have done a clinical study on the inntratumoral expressions of FGFR family genes. Consequently, we considered that not only FGFR1 but also FGR2 could be target genes for treatments. We produced a FGFR2-inhibiting vector using an adenoviral vector (Ad-shFGFR2). in vitro experiments using the Ad-shFGFR2 were performed against a lung cancer cell line A549, which has high expression levels of FGFR2. The Ad-shFGFR2 effectively knocked down the FGFR2 expression (approximately 85%). However, MTT assays revealed that the Ad-shFRFR2 did not effectively inhibit the growth of tumor cells. Therefore, considering that FGFR2 may not be a simple driver gene, we perform an experimental study using co-transfection with other candidates of driver genes.